Biotech · Public company · Fort Worth, TX, US

Actuate Therapeutics, Inc.

Ticker ACTU · SEC CIK 0001652935

Track this companyFree. Adds Actuate Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials84 recruiting or active

Pipeline programs15From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline15

9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland CarcinomaPHASE2 · WITHDRAWN · started Dec 18, 2030ClinicalTrials.gov NCT04832438 · fetched Nov 12, 2026
9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)PHASE1 · RECRUITING · started Sep 22, 2025ClinicalTrials.gov NCT06896188 · fetched Nov 12, 2026
FOLFIRINOX + Elraglusib + Losartan In Pancreatic CancerPHASE2 · ACTIVE_NOT_RECRUITING · started Mar 21, 2022ClinicalTrials.gov NCT05077800 · fetched Nov 12, 2026
9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic AdenocarcinomaPHASE2 · TERMINATED · started Jan 26, 2022ClinicalTrials.gov NCT05239182 · fetched Nov 12, 2026
9-ING-41 Plus Carboplatin in Salivary Gland CarcinomaPHASE2 · ACTIVE_NOT_RECRUITING · started Sep 17, 2021ClinicalTrials.gov NCT05010629 · fetched Nov 12, 2026
Actuate 1901: 9-ING-41 in MyelofibrosisPHASE2 · COMPLETED · started Aug 20, 2020ClinicalTrials.gov NCT04218071 · fetched Nov 12, 2026
9-ING-41 in Pediatric Patients With Refractory Malignancies.PHASE1 · TERMINATED · started Jun 5, 2020ClinicalTrials.gov NCT04239092 · fetched Nov 12, 2026
9-ING-41 in Patients With Advanced CancersPHASE2 · ACTIVE_NOT_RECRUITING · started Jan 4, 2019ClinicalTrials.gov NCT03678883 · fetched Nov 12, 2026